

ondine



For Immediate Release

Ondine Announces Appointment of Dr. Timothy Rose as the Chairman of its Clinical Advisory Board

Vancouver, Canada – August 20, 2007 - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP) a medical technology company focused on photodisinfection technology, announces that Dr. Timothy Rose, DDS has accepted the position as chairman of its Clinical Advisory Board (CAB). Dr. Rose is a former president of both the American Academy of Periodontology and the American Dental Association. In addition to practising Periodontology in Wisconsin, Dr. Rose also holds positions on various boards and committees. Over the course of his career, Dr. Rose has received numerous prestigious awards in recognition of his contributions to dentistry.

“We are very pleased to have Dr. Rose take on the role as chairman of our Clinical Advisory Board”, said Carolyn Cross, President & CEO of Ondine. “Dr. Rose’s experience and expertise will be invaluable as Ondine expands its development and commercialization efforts of Periowave™ and other photodisinfection products.”

Ondine’s Clinical Advisory Board members include: Dr. Steve Bruce (General Dentist - Idaho), Dr. Greg Chadwick (Endodontist - North Carolina), Dr. Sharon Compton (Director of Dental Hygiene Program – University of Alberta), Dr. Richard Darveau (Professor - University of Washington), Dr. Robert Genco (Periodontist - University of Buffalo), Professor Gareth Griffiths (Professor, University of Sheffield) and Ms. Trisha O’Hehir (Editor of Hygiene Town - Arizona). For more information about this board, please visit the Company’s website.

About Periowave™ and Photodisinfection

Periowave™ is a Photodisinfection system developed by Ondine that utilizes low-intensity lasers and wavelength-specific, light-activated photosensitive compounds to specifically target and destroy microbial pathogens and reduce the symptoms of disease. The compounds are topically applied and lasers of appropriate wavelength and intensity are used to disinfect the treatment site.

About Ondine Biopharma Corporation

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on creating and commercializing leading-edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance.

The Company is headquartered in Vancouver, British Columbia, Canada, with a research laboratory in Bothell, Washington, USA, and an international office in St. Michael, Barbados. For additional information, please visit the Company's website at: www.ondinebiopharma.com.

Forward-Looking Statements:

Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's filings.

The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release

For further information please contact:

Carolyn Cross	Christina Bessant	Nominated Adviser
President and	Investor Relations	Neil Johnson /
Chief Executive Officer		Ryan Gaffney
Ondine Biopharma Corporation	The Equicom Group Inc.	Canaccord Adams Ltd
(604) 669-0555	(416) 815-0700 ext. 269	+44(0)20 7050 6500
ccross@ondinebiopharma.com	cbessant@equicomgroup.com	